中国批准Akeso的AK152AK152对阿尔茨海默氏病进行试验,这是针对氨基甲状腺的双性抗体,可以增强脑传递。 China approves Akeso’s AK152 trial for Alzheimer’s, a bispecific antibody targeting amyloid plaques and enhancing brain delivery.

AKESO公司已获得中国监管部门批准, 开始AK152临床试验, 这是中国第一针对阿尔茨海默氏病的抗体。 Akeso, Inc. has received Chinese regulatory approval to begin clinical trials for AK152, a first-in-China bispecific antibody targeting Alzheimer’s disease. 治疗目的是清除β-粉样蛋白斑块,通过与β-粉样蛋白和血脑屏障受体结合来增强脑部的输送,与现有治疗方法相比,改善透. The therapy aims to clear amyloid-beta plaques and enhance brain delivery by binding to both amyloid-beta and a blood-brain barrier receptor, improving penetration compared to existing treatments. 临床前数据显示,动物模型中改善了斑块清除和减少神经病理,具有良好的安全性. Preclinical data show improved plaque clearance and reduced neuropathology in animal models, with a favorable safety profile. 该试验将评估其作为下一代疾病改变疗法的潜力。 The trial will assess its potential as a next-generation disease-modifying therapy.